MTOR and cancer: In addition to the above-mentioned two pathways, m6A affects cancer pathogenesis and progression via other classical pathways, including the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), p53, EMT, mitogen-activated protein kinase (MAPK), and p38/extracellular signal-regulated kinase (ERK).